J Korean Breast Cancer Soc.  2000 Aug;3(1):51-59. 10.4048/jkbcs.2000.3.1.51.

Cyclin D1 Expression and Patient Outcome After Tamoxifen Therapy in Estrogen Receptor Positive Breast Cancer

• Han S
• Kim HY
• Park K
• Bae BN
• Kim KH
• Kim HJ
• Kim YD
• Yuh YJ
• Kim SR

• KMID: 1906279
• DOI: http://doi.org/10.4048/jkbcs.2000.3.1.51

Abstract

BACKGROUND AND OBJECTIVES: Cyclin D1 expression is closely related with ER in breast cancer. We conducted this study to evaluate whether therapeutic response to tamoxifen is varied with levels of cyclin D1 expression in ER positive breast cancer patients.
METHODS
Immunohistochemical assay for cyclin D1 protein was performed in 66 patients treated with tamoxifen for more than 2 year. Patient survival and correlation between cyclin D1 expression and biologic data of the patients were analyzed.
RESULTS
Cyclin D1 expression was detected in 46 (69.7%) and significantly reduced in poorly differentiated cancer (p=0.023). Cyclin D1 expression was high in the tumors expressing Myc (15/15 vs. 31/51; p=0.002), and was markedly increased in the tumors in which p27Kip1 expression was repressed (30/38, 78.9%). However, the difference was not ststistically significant (p=0.051). There was no significant relationship between cyclin D1 expression and S-phase. Patients with tumors expressing cyclin D1 showed better disease free survival and overall survival but the difference was not statistically significant.
CONCLUSIONS
Cyclin D1 expression was associated with cell differentiation bit not useful in discriminating high risk group with tamoxifen treatment. Cyclin D1 may have a role other than cell cycle regulator in ER positive breast cancer, such as differentiation signal.

Keyword

Differentiation; Myc; p27kip1; Prognosis; Treatment

MeSH Terms

Breast Neoplasms*
Breast*
Cell Cycle
Cell Differentiation
Cyclin D1*
Cyclins*
Disease-Free Survival
Estrogens*
Humans
Prognosis
Tamoxifen*
Cyclin D1
Cyclins
Estrogens
Tamoxifen